The primary endpoint for the phase 3 is to "detect a 20 percent difference in clinical events between the patients taking AGI-1067 and those patients on standard of care alone."
Although I am unsure whether the 2.3% reduction in plaque that was shown in Cart-2 can be taken as sign that the number of events will decrease in the AGI-1067, the risk comes from the lack of secondary endpoints in the phase 2 trials to measure the number of clinical events (especially for Cart-2 where the FDA expanded the trial beyond the initial aim of the company, whereas Cart-1 measured restenosis rates).
From Cart-1 you can see in Figure five in the online article referred below that restenosis rates were significantly lower with AGI-1067. My question is..can you infer/guess that other clinical events will also be lower with just that piece of info with sufficient confidence to bet on it..? I would say no..
Market Data 
Markets 
AI
